Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Primary cardiac lymphoma

Primary cardiac lymphoma is an extranodal lymphoid neoplasm in which the heart and/or pericardium are the exclusive or predominant sites of disease at presentation. The most restrictive definition includes only cases confined to these structures; other case series include limited extracardiac involvement when the principal mass and manifestations are cardiac. Stating the criterion used makes it possible to distinguish this entity from cardiac involvement in disseminated systemic lymphoma and to interpret published data correctly.

The predominant histological type is diffuse large B-cell lymphoma, also known as DLBCL. The right-sided chambers, atrioventricular groove, myocardium and pericardium are frequently involved, although left-sided disease is possible. This condition combines the potential aggressiveness of lymphoma with the immediate risk posed by infiltration of an essential organ. Timely diagnosis can permit a marked response to systemic therapy even when masses are extensive: this guides the choice of biopsy from the outset and limits the role of resection as routine oncological treatment.

Etiology, predisposition and pathogenesis

The disease is very rare, and epidemiological knowledge is mainly derived from retrospective case series and pooled published cases. Secondary cardiac involvement by lymphoma is more common overall. Primary disease is described predominantly in adults, but the age range is broad. Site frequencies, survival and response depend on the definition adopted, the diagnostic era and patient selection, so figures from case series do not represent population estimates.

Immunosuppression, including that associated with HIV or transplantation, is a relevant setting for some cardiac lymphomatous proliferations; however, many cases arise in people without a known immune deficiency. Impaired immune surveillance and, in certain entities, Epstein–Barr virus infection may promote clonal expansion. Detection of EBV in tissue and the clinical context have classification value, whereas a history of positive serology alone is common in the population and does not establish that the virus caused the lymphoma.

The molecular pathogenesis reflects the heterogeneity of aggressive B-cell lymphomas, with abnormalities in the regulation of proliferation, apoptosis and differentiation programs. Cardiac location alone does not identify a single genetic abnormality or a universal therapeutic target. Characterization must therefore follow current hematopathological classification, distinguishing DLBCL not otherwise specified from categories with different biology and treatment, including those associated with immune deficiency or specific rearrangements.

Pathological anatomy and related entities

Lymphoma may form an infiltrating mass, diffuse wall thickening or multiple nodules. The proliferation extends between myocardial fibers and along epicardial, vascular or pericardial structures; an intracavitary component may be only the most visible part of the process. In large B-cell forms, the tissue shows large atypical lymphoid cells, high proliferative activity and a diffusely disrupted architecture. Necrosis and specimen fragility may render a small sample inadequate.

The immunophenotype establishes the lymphoid lineage and, in appropriate cases, the expression of CD20, PAX5 and other B-cell markers. CD10, BCL6, MUM1, BCL2, MYC and Ki-67 contribute to classification; additional markers are selected according to morphology. Protein coexpression of MYC and BCL2 and rearrangements of the corresponding genes are distinct findings. FISH testing clarifies abnormalities that may change classification and the therapeutic strategy, while EBER and other viral tests address specific questions.

Primary effusion lymphoma, associated with HHV8, may involve pericardial fluid and requires an assessment distinct from that of a mass-forming cardiac DLBCL. HHV8-negative large B-cell lymphomas associated with effusion and fluid overload also exist and are recognized by modern classifications using specific criteria. Fluid localization, the absence or presence of masses, phenotype and viral status must be considered together: finding malignant lymphoid cells in the pericardium does not automatically assign a case to a single category.

Another distinction concerns fibrin-associated lymphoma, which may be discovered in thrombotic material, on prostheses or within other cardiac lesions. These proliferations, often microscopic and associated with EBV, may behave differently from an infiltrating myocardial mass. Their identification requires correlation between histological findings and disease distribution; the prognosis and treatment of aggressive cardiac lymphoma must not be applied indiscriminately to every lymphoid focus found in the heart.

Pathophysiology of cardiac involvement

Myocardial infiltration reduces compliance and may impair contractile function. The right ventricle and right atrium may be affected, with impaired filling, tricuspid abnormalities or reduced output. Growth along the atrioventricular groove may encase coronary structures; its effect on perfusion depends on actual invasion and compression, since encasement of a vessel does not necessarily imply occlusion.

Involvement of the conduction system is clinically important. Infiltration of the septum and nodal regions may cause atrioventricular block, bradycardia or intraventricular conduction disturbances; myocardial changes promote supraventricular and ventricular arrhythmias. An electrical abnormality may precede demonstration of a large mass. Regression with treatment may improve conduction, but scar tissue and persistent injury make reversibility variable.

Vena caval obstruction causes increased upstream venous pressure, with facial and upper-limb edema when the superior vena cava is involved. In the pericardium, infiltration and impaired drainage may cause effusion, potentially progressing to tamponade; in other patients, restrictive or constrictive physiology predominates. Superimposed thrombus and fragmentation of intracavitary components can add embolic risk, while rapid growth shortens the time available for hemodynamic adaptation.

Clinical manifestations and initial assessment

Presentation may include dyspnea, fatigue, chest pain, palpitations, edema and reduced exercise tolerance. Fever, night sweats and weight loss suggest lymphomatous disease but may be absent. Syncope, marked bradycardia, tamponade or superior vena cava syndrome are particularly significant modes of presentation. The absence of palpable lymphadenopathy remains fully compatible with predominant extranodal involvement of the heart.

The medical history establishes symptom progression, previous lymphomas or other neoplasms, transplantation, immunosuppressive medications, HIV infection and cardiotoxic treatments. Prostheses, implanted devices, procedures and a history of effusions are also relevant because they may alter the diagnostic context. Drugs that slow conduction and metabolic disturbances must be considered when the first sign is a block, without stopping the search for an infiltrative cause if suspicion persists.

Physical examination looks for systemic congestion, hypoperfusion, rhythm disturbances, murmurs, jugular venous distension and signs of vena caval obstruction. Hypotension, tachycardia, dyspnea at rest or syncope calls for prompt assessment of stability. Examination of the lymph nodes, liver and spleen, together with a neurological assessment, completes the evaluation. Symptoms may arise simultaneously from the mass, effusion and arrhythmia; attributing everything to nonspecific heart failure risks overlooking a treatable component.

The ECG documents conduction and rhythm, while telemetry or prolonged monitoring is used when arrhythmic risk is present. Complete blood count, electrolytes, renal and liver function, lactate dehydrogenase and uric acid help assess disease burden and treatment safety. Troponin and natriuretic peptides describe cardiac injury and stress in the appropriate context. Elevated LDH supports suspicion of high turnover but is nonspecific; minimally abnormal blood tests do not rule out a localized neoplasm.

Imaging and anatomic-functional characterization

Transthoracic echocardiography identifies masses, thickening, effusion and effects on blood flow. The examination should assess both ventricles, valves, estimated pulmonary pressure and visible venous outlets. Transesophageal echocardiography further evaluates posterior structures, the septum and intracavitary relationships when needed and may assist tissue sampling. The combination of a right-sided mass, infiltration and effusion suggests malignancy but is compatible with several histological types.

Cardiac magnetic resonance imaging clarifies intramural extent, epicardial involvement and residual function. Cine imaging, tissue-characterization sequences and postcontrast evaluation characterize tumor tissue, edema, necrosis and associated thrombus. Relatively homogeneous infiltration or spread along the grooves may suggest lymphoma; variability of findings and overlap with other neoplasms prevent a signal criterion from replacing histological examination.

Contrast-enhanced CT is useful for mapping the venae cavae, coronary arteries, mediastinum and extracardiac masses, particularly when rapid examination is advantageous. Distinguishing vascular encasement, compression and invasion affects procedures and risk assessment. The distribution of lymphadenopathy may provide a more accessible diagnostic site than the heart and help identify systemic lymphoma with secondary cardiac involvement.

FDG PET/CT has a central role in FDG-avid lymphomas for staging and response assessment. Cardiac findings must be interpreted in light of physiological myocardial uptake and the preparation protocol used; a protocol designed to suppress myocardial signal may help when the local diagnostic question requires it. Uptake intensity and individual SUV measurements do not establish histological type and can be affected by inflammation or recent treatment.

Obtaining the diagnosis and main differential diagnoses

The choice of biopsy is aimed at obtaining adequate material rapidly with the lowest reasonable risk. An accessible lymph node or extracardiac lesion may be preferable; otherwise, imaging-guided endomyocardial or mass biopsy, or a targeted surgical procedure, is considered. Right-sided location may allow transvenous access, but mobility, perforation risk and relationships to valves and the conduction system require individualized planning.

When drainage is indicated, pericardial fluid is submitted for cytology, cell-block preparation and complementary testing. Flow cytometry may identify an abnormal lymphoid population; the laboratory must be notified in advance so fresh material is preserved under appropriate conditions. Negative cytology does not exclude lymphoma, particularly when the effusion is paucicellular, the infiltrated tissue does not communicate with the cavity or the specimen has degenerated. Sample adequacy must be assessed before the diagnostic investigation is considered complete.

Administration of corticosteroids before sampling can reduce the tumor-cell population and make classification more difficult. When circumstances permit, the specimen is obtained before lympholytic therapy. A life-threatening emergency may require a different choice, to be agreed promptly among the hematologist, cardiologist and pathologist, with documentation of treatment and timing. The need to preserve diagnostic yield must coexist with the priority of maintaining effective circulation.

The differential diagnosis includes sarcomas, metastases, thrombi, infiltrative inflammatory processes and, in certain settings, infections. Angiosarcoma may share a right-sided location and effusion; endothelial or lymphoid tissue characterization distinguishes conditions requiring profoundly different treatments. A mediastinal lymphoma directly invading the heart must be recognized according to its original distribution. In isolated effusions, classification must also consider lymphoid entities associated with serous cavities.

Staging, risk and pretreatment investigations

Hematological staging combines PET/CT, clinical examination and laboratory testing to document nodal and extranodal sites. Bone marrow biopsy is reserved for questions in which discordant or alternative marrow disease would change management, rather than being added automatically to every PET scan. Stage, LDH, age, performance status and number of extranodal sites contribute to the International Prognostic Index; local cardiac severity must be described separately because it can be high even when disease is anatomically limited.

Assessment of the central nervous system is guided by symptoms, histological type and risk profile and includes, when indicated, MRI and cerebrospinal-fluid testing with cytology and flow cytometry. Reported neurological relapses in cardiac lymphoma warrant attention, but cardiac location alone is insufficient evidence to apply the same prophylaxis to everyone. CNS-IPI, tumor biology and other sites inform a specialist decision, taking account of the limitations of evidence and the toxicity of central nervous system-directed treatment.

Before immunochemotherapy, infectious disease status is established, including HIV, hepatitis B and hepatitis C, and prevention of HBV reactivation is planned when indicated with anti-CD20 therapy. Renal function, electrolytes, uric acid and tumor burden guide prevention of tumor lysis. Cardiovascular assessment includes biventricular function, valves, effusion, gradients and conduction, in addition to ejection fraction. These measurements provide a baseline for distinguishing response, progression and toxicity.

Immunochemotherapy and local treatment

For CD20-positive DLBCL, potentially curative systemic therapy is the cornerstone of treatment. R-CHOP combines rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone and is widely represented in reported experience with primary cardiac disease. The regimen, number of cycles and intensity are determined by classification, stage, risk and tolerability. The presence of the tumor in the heart requires clinical adaptation of the treatment pathway, without assuming that location alone precludes a curative strategy.

Contemporary guidelines for large B-cell lymphoma include Pola-R-CHP, in which polatuzumab vedotin replaces vincristine, among preferred options for certain risk profiles. Its use in cardiac lymphoma derives from general assessment of the histological type and patient factors: no randomized comparison dedicated to the cardiac site is available. Different regimens may be discussed for lymphomas with high-risk biological features, avoiding the mistaken equivalence of MYC expression by immunohistochemistry and a genetic rearrangement.

Doxorubicin presents a particular challenge when infiltration has already impaired the myocardium or the patient has had previous exposure. The balance includes the potential for recovery with lymphoma response and the additional risk from anthracyclines. If contraindicated, alternative regimens are considered, such as replacing doxorubicin with etoposide in R-CEOP, or other strategies agreed with hematology; liposomal formulations and cardioprotection may be assessed in appropriate settings. Reduced toxicity must be weighed against expected oncological effectiveness.

A prephase or modified initial administration may be considered in frail patients or those with extensive infiltration, after diagnostic material has been obtained. Its purpose and reassessment must be explicit, because even corticosteroids can cause rapid lysis. The immediate risk does not concern drugs alone: mass necrosis, changes in blood flow and injury to the infiltrated wall may accompany an effective response. In high-risk presentations, treatment starts in a monitored setting with the capacity for timely cardiological intervention.

Surgery is primarily diagnostic or directed at a mechanical complication. Extensive resection is not normally required to eradicate a treatment-sensitive lymphoma and may delay the start of treatment. Debulking or reconstruction is discussed when a critical obstruction cannot await response, when diagnosis remains unobtainable through less invasive routes or in other selected circumstances. Drainage of tamponade, by contrast, is urgent treatment for pericardial compromise.

Radiotherapy may have a role in situations defined by the hematological treatment pathway, such as an appropriately characterized localized residual lesion. Radiation dose to cardiac structures and prior therapies require careful planning; a residual mass without metabolic activity does not automatically represent viable lymphoma requiring irradiation. In relapsed or refractory disease, salvage regimens, autologous transplantation, CAR-T cells, bispecific antibodies and other B-cell lymphoma treatments are considered according to timing, eligibility and indications. For immune-effector therapies, cardiac reserve and risk of cytokine release syndrome form part of the initial assessment.

Safety during the first cycles and supportive care

Tumor lysis syndrome can cause hyperuricemia, potassium, phosphate and calcium disturbances, renal failure and arrhythmias. Prevention and monitoring are tailored to tumor volume, proliferation, renal function and therapy; allopurinol or rasburicase is selected according to risk. Hydration requires particular care in heart failure, obstruction or effusion: a standard protocol not adapted to cardiac physiology can worsen congestion.

Hemodynamic monitoring in the most severely affected patients looks for worsening effusion, acute dysfunction, changes in obstruction and arrhythmias. Rapid regression of an infiltrating mass can rarely be associated with injury or rupture of the wall; this possibility justifies targeted surveillance without assuming that a complication is inevitable during response. Frequent echocardiograms are scheduled according to anatomy and clinical course, with increased monitoring if pain, hypotension or sudden deterioration occurs.

Symptomatic atrioventricular block may require temporary or permanent pacing, considering potential reversibility and the safety of device access in the presence of the mass. Device choice and timing are agreed with an electrophysiologist. Heart failure treatment, anticoagulation when specifically indicated, infection prophylaxis and hematological support accompany care. In patients with HIV or transplantation, control of infection, drug interactions and immunosuppression management are integrated into the plan.

Response, prognosis and surveillance

Metabolic response is interpreted using criteria for FDG-avid lymphomas, integrating PET, the clinical picture and timing relative to treatment. Complete metabolic remission may coexist with a residual scar mass. Conversely, a persistent focus must be assessed for possible viable disease, inflammation or another cause; when the result would change a major treatment decision, confirmation or targeted reassessment may prevent action based on a false positive.

Cardiac recovery is monitored in parallel with hematological remission. Reduction of effusion, resolution of obstruction, improvement in function and restoration of conduction may occur on different timelines. Persistent arrhythmia or residual dysfunction does not in itself demonstrate refractory disease, just as apparently normalized function does not exclude extracardiac disease. Functional imaging and staging address complementary questions.

Prognosis depends on histological type, extent of disease, immune status, general condition, initial cardiovascular injury and response. Delayed diagnosis and instability contribute to early mortality, but durable remissions are possible. Medians from pooled published cases combine different eras and treatments and are affected by selection bias. Follow-up looks for relapse and toxicity according to symptoms and risk; indiscriminate repeat PET scans in remission do not replace planned clinical and cardiological surveillance.

Complications

Disease complications include tamponade, flow obstruction, vena caval syndrome, heart failure, conduction block, ventricular arrhythmias, ischemia and embolization. Extracardiac spread and possible neurological involvement add organ injury. The speed of growth makes recognition of clinical change particularly important before a compensated state becomes critical.

Treatment-related complications include infections and myelosuppression, tumor lysis, infusion reactions, viral reactivation, myocardial toxicity and, with applicable therapies, immune-mediated or cytokine-activation events. Risk varies with regimen, physiological reserve and phase of treatment. Ongoing collaboration between hematology and cardiology helps distinguish toxicity, response with anatomical changes and progression, while maintaining lymphoma control as a goal alongside circulatory safety.

References
  1. Zhuang S et al. Primary cardiac lymphoma: a clinicopathological study of 121 cases. Frontiers in Oncology. 2025;14:1509100.
  2. Thieblemont C et al. Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. HemaSphere. 2025;9(9):e70207.
  3. Di Napoli A et al. Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Archiv. 2023;483:299-316.
  4. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  5. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  6. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  7. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  8. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  9. Kassab J et al. Case report: Primary cardiac lymphoma manifesting as superior vena cava syndrome. Frontiers in Cardiovascular Medicine. 2023;10:1257734.
  10. Takeda K et al. Higher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false-negative cytology: A multi-institutional analysis. Cytopathology. 2025;36(1):31-40.
  11. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.
  12. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.